Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M170,842Revenue $M44,033Net Margin (%)10.0Z-Score3.0
Enterprise Value $M181,066EPS $1.5Operating Margin %14.4F-Score4
P/E(ttm))38.7Cash Flow Per Share $6.3Pre-tax Margin (%)12.6Higher ROA y-yN
Price/Book3.410-y EBITDA Growth Rate %3.1Quick Ratio1.6Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %-6.3Current Ratio1.8Lower Leverage y-yN
Price/Cash Flow7.1y-y EBITDA Growth Rate %-6.6ROA % (ttm)4.2Higher Current Ratio y-yN
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)8.9Less Shares Outstanding y-yY
Payout Ratio %115Shares Outstanding M2,922ROI % (ttm)6.0Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKJean-Marie Eveillard 2014-03-31 Add0.34%$49.49 - $57.47
($54.09)
$ 587%Add 15820.6%2,236,839
MRKDavid Dreman 2014-03-31 Buy 0.02%$49.49 - $57.47
($54.09)
$ 587%New holding, 4431 sh.4,431
MRKJoel Greenblatt 2014-03-31 Buy $49.49 - $57.47
($54.09)
$ 587%New holding, 3567 sh.3,567
MRKJames Barrow 2014-03-31 Reduce-0.48%$49.49 - $57.47
($54.09)
$ 587%Reduce -22.72%22,739,030
MRKDodge & Cox 2014-03-31 Reduce-0.45%$49.49 - $57.47
($54.09)
$ 587%Reduce -18.11%39,959,196
MRKVanguard Health Care Fund 2014-03-31 Reduce-0.15%$49.49 - $57.47
($54)
$ 587%Reduce -2.58%35,616,848
MRKGeorge Soros 2014-03-31 Sold Out -0.06%$49.49 - $57.47
($54.09)
$ 587%Sold Out0
MRKJohn Hussman 2014-03-31 Sold Out -0.01%$49.49 - $57.47
($54)
$ 587%Sold Out0
MRKGeorge Soros 2013-12-31 Buy 0.06%$45.09 - $50.18
($47.86)
$ 5821%New holding, 150000 sh.150,000
MRKRuane Cunniff 2013-12-31 Buy $45.09 - $50.18
($47.86)
$ 5821%New holding, 4075 sh.4,075
MRKJean-Marie Eveillard 2013-12-31 Reduce-0.16%$45.09 - $50.18
($47.86)
$ 5821%Reduce -98.76%14,050
MRKLeon Cooperman 2013-12-31 Sold Out -0.15%$45.09 - $50.18
($47.86)
$ 5821%Sold Out0
MRKCharles Brandes 2013-12-31 Reduce-0.14%$45.09 - $50.18
($47.86)
$ 5821%Reduce -8.39%2,476,201
MRKJean-Marie Eveillard 2013-09-30 Reduce-0.16%$46.55 - $48.58
($47.88)
$ 5821%Reduce -49.6%1,134,041
MRKGeorge Soros 2013-09-30 Sold Out -0.13%$46.55 - $48.58
($47.88)
$ 5821%Sold Out0
MRKJoel Greenblatt 2013-09-30 Sold Out -0.05%$46.55 - $48.58
($47.88)
$ 5821%Sold Out0
MRKJames Barrow 2013-06-30 Add1.32%$44.35 - $49.44
($46.81)
$ 5824%Add 134.86%29,318,754
MRKCharles Brandes 2013-06-30 Add0.48%$44.35 - $49.44
($46.81)
$ 5824%Add 43.39%2,703,540
MRKGeorge Soros 2013-06-30 Buy 0.13%$44.35 - $49.44
($46.81)
$ 5824%New holding, 250000 sh.250,000
MRKJean-Marie Eveillard 2013-06-30 Add0.1%$44.35 - $49.44
($46.81)
$ 5824%Add 46.32%2,250,286
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
MRK Jean-Marie Eveillard 2014-03-312,236,8390.080.34+15820.6%
MRK David Dreman 2014-03-314,43100.02New Buy
MRK Joel Greenblatt 2014-03-313,56700New Buy
MRK Ruane Cunniff 2014-03-314,40900+8.2%
MRK Prem Watsa 2014-03-3112,00000.05
MRK Charles Brandes 2014-03-312,451,1250.081.8-1.01%
MRK Vanguard Health Care Fund 2014-03-3135,616,8481.225.7-2.58%
MRK Mario Gabelli 2014-03-31160,3160.010.05-18.07%
MRK Dodge & Cox 2014-03-3139,959,1961.372.3-18.11%
MRK James Barrow 2014-03-3122,739,0300.781.8-22.72%
MRK George Soros 2014-03-31000Sold Out
MRK John Hussman 2014-03-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FRAZIER KENNETH CChairman, President & CEO 2014-07-10Sell9,987$58.030.53view
GRADDICK WEIR MIRIAN MExe V-P, HR 2014-07-07Sell180,047$59.16-1.39view
Deese Willie AExe V-P & Pres. MMD 2014-06-27Sell72,290$58.260.14view
FRAZIER KENNETH CChairman, President & CEO 2014-06-10Sell9,985$58.060.48view
Schechter Adam HEVP & Pres-Global Human Health 2014-05-14Sell10,527$55.914.35view
FRAZIER KENNETH CChairman, President & CEO 2014-05-09Sell10,220$556.07view
FRAZIER KENNETH CChairman, President & CEO 2014-04-10Sell10,047$57.241.92view
Kuhlik Bruce NExe V-P & Gen Counsel 2014-04-04Sell145,225$56.433.38view
Golestani ClarkEVP & Chief Info Officer 2014-02-14Sell5,990$55.475.17view
Heller Bridgette PExe.VP & Pres.Con.Hlth.Care 2014-02-13Sell43,870$55.046view

Press Releases about MRK :

    Quarterly/Annual Reports about MRK:

      News about MRK:

      Articles On GuruFocus.com
      UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
      U.S. Markets Regain Losses from Last Week Jul 14 2014 
      Abner Herrman Is Increasing Position in the Pharmaceutical Sector Jul 11 2014 
      U.S. Equity Markets Continue to Hit New Highs Jun 15 2014 
      Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 
      Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014? May 05 2014 
      Wrong Marketing Lesson by Big Pharma May 03 2014 
      Vanguard Health Care Fund's Top Quarterly Holdings Apr 30 2014 
      Bill Nygren Comments on Merck Apr 10 2014 
      Abbvie Inc. (ABBV) Dividend Stock Analysis Mar 21 2014 


      More From Other Websites
      Gilead Drug Combination Cures Hepatitis C in HIV Patients Jul 20 2014
      Gilead Drug Combination Cures Hepatitis C in HIV Patients Jul 20 2014
      Merck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis... Jul 17 2014
      Studies see new risks for cholesterol drug niacin Jul 16 2014
      Merck Completes Squeeze-Out of AZ Electronic Materials Jul 16 2014
      Merck Serono Announces Global Grants Program to Fund Scientific Innovation Jul 16 2014
      Merck Serono Appoints Luciano Rossetti as Global Head of R&D Jul 16 2014
      [$$] Merck Pushes to Revive Beef Drug Jul 15 2014
      Perrigo retreats after analyst sees limited potential buyers Jul 15 2014
      Tax Reform, Not Tax Inversions, Will Rescue The U.S. Pharma, Bio, And Medical-Device Industries Jul 15 2014
      Merck KGaA’s Biopharmaceutical Division Appoints Luciano Rossetti as Global Head of R&D Jul 14 2014
      Merck KGaA pharma chief says looking at mid-size deals - paper Jul 12 2014
      Senators Ask Gilead To Explain Sovaldi Pricing Jul 11 2014
      If Big Pharma Ignores Antibacterial R&D, Where Will We Get The Drugs To Treat Superbugs? Jul 11 2014
      Dengue Vaccine Shows Promise Against 3 Out of 4 Viruses Jul 10 2014
      Bristol-Myers Seeking Nivolumab Approval In Melanoma Jul 10 2014
      Pharma's Poor Reputation Doesn't Help In The Fight Against Superbugs Jul 10 2014
      Study Shows No Link Between Gardasil And Blood Clots Jul 08 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide